65,437 trials
Rheumatoid Arthritis
Primary: Simple Disease Activity Index (SDAI) Remission Rate at Week 48 in mFAS — 25; 27 Participants
Melanoma
Primary: Overall Survival (OS) — 16.1; 25.0; 30.0 Months — p=0.02
Substance-Related Disorders · Mental Disorder · Social Stigma
Primary: CHW Stigma Towards Substance Use — -0.88 change in units on a scale
Opioid Abuse, Unspecified
Primary: Change in Average Per-clinician Log Total Weekly MME Between Baseline and Intervention for Opioid Naïve and At-Risk Patients (Below 50 MME Daily Dose Rxs) — -0.14; -0.05…
Cancer · Solid Tumor · Patient Empowerment
Primary: Healthcare Time — 265.97; 339.54 minutes
Hepatocellular Carcinoma
Primary: Delivered Activity of Tc-99m MAA (MBq) for Whole Body — 67.322 MBq
Diagnosis of Schizophrenia Spectrum Disorders
Primary: Metacognition Assessment Scale-Abbreviated (MAS-A) — 11.53; 14.22; 14.22; 14.25 score on a scale
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Overactive Bladder · Overactive Detrusor · Overactive Bladder Syndrome
Primary: Pain: VAS — 25; 16 units on a scale, 0-100
Febrile Illness
Primary: Proportion of Survival With Symptom Resolution — 96.9 percentage of participants
Breast Cancer · Overweight or Obesity
Primary: Number of Patients With 5 Percent Weight Loss (in SLOW-BWL) — 16 Participants
Parkinson's Disease · Parkinsonism
Primary: Frequency of Adverse Events — 22; 31; 25; 31 TEAEs
Familial Chylomicronemia Syndrome
Primary: Percent Change From Baseline in Fasting TG at Month 6 — 11.52; -10.85; -31.99 percent change — p==0.0009
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 36.0; 39.1; 8.3; 35.3 Percentage of participants
Hearing Aids · Hearing Loss
Primary: Profile of Hearing Aid Benefit — 23.34; 23.27; 23.33 score on a scale